Sarepta Therapeutics, Inc. SRPT Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Sarepta Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sarepta Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sarepta Therapeutics, Inc.'s accounts payable?
- Sarepta Therapeutics, Inc. (SRPT) reported accounts payable of $70.38M in Q1 2026.
- How has Sarepta Therapeutics, Inc.'s accounts payable changed year-over-year?
- Sarepta Therapeutics, Inc.'s accounts payable decreased by 54.9% year-over-year, from $156.11M to $70.38M.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s accounts payable has grown at a 20.4% compound annual growth rate (CAGR), from $111.09M to $280.84M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.